Dublin, Ireland, Ireland · Est. 2003 · 2,600 employees
Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines in the fields of neurology, psychiatry, sleep medicine, and oncology.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 21 drugs with upcoming expirations
Pipeline
By Phase
7 drugs in development
By Therapeutic Area
top 2
R&D Momentum
66/100
Pipeline Velocity
36/100
Trial Completion Rate
77/100
Pipeline Concentration
43/100
Pipeline Freshness
81/100
Strategic Signals
Activity
Last 14 days
Long-term Follow-up of a Multicentre, Non-interventional, Prospective Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy
8-K
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma
A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures
A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
8-K
A Double-Blind, Sponsor-Unblinded, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single-Ascending Doses of JZP047 and an Open-Label Food Effect Study of JZP047 in Healthy Male and Female Participants
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Details
Company Overview
$6.5B
Mkt Cap
$376.1M
Revenue
$2.4B
Cash
Therapeutic Focus
Recent SEC Filings
8-K
8-K
8-K
8-K
8-K
Pipeline
Regulatory
Plaquenil — PLAQUENIL
Application NDA009768
Robinul — DARTISLA ODT
Application NDA215019 (NDA)
Aphexda — APHEXDA
Application NDA217159 (NDA)
Cymbalta — CYMBALTA
Application NDA021427
Cymbalta — CYMBALTA
Application NDA021427
Aleve — ALEVE
Application NDA020204
Tepadina — TEPYLUTE
Application NDA216984 (NDA)
Tepadina — TEPADINA AND SODIUM CHLORIDE, TEPADINA
Application NDA208264
Anzupgo — ANZUPGO
Application NDA219155 (NDA)
Anzupgo — ANZUPGO
Application NDA219155 (NDA)
Aleve — ALEVE
Application NDA020204
Tepadina — TEPADINA AND SODIUM CHLORIDE, TEPADINA
Application NDA208264
Thalitone — HEMICLOR
Application NDA218647 (NDA)
8-K
Accession: 0001232524-26-000056
8-K
Accession: 0001628280-26-067275
8-K
Accession: 0001628280-26-065497
8-K
Accession: 0001193125-26-399425
8-K
Accession: 0001628280-26-061978
8-K
Accession: 0001193125-26-377073
8-K
Accession: 0001628280-26-058864
8-K
Accession: 0001193125-26-341270
8-K
Accession: 0001193125-26-342667
8-K
Accession: 0001232524-26-000044
Thiola Ec — TIOCYSTIN
Application NDA212927 (NDA)
Trexall — TREXALL
Application ANDA040385
Aleve — ALEVE
Application NDA020204
Cymbalta — DULOXETINE HYDROCHLORIDE
Application NDA219131 (NDA)
Cymbalta — DULOXETINE HYDROCHLORIDE
Application NDA219131 (NDA)
Tepadina — TEPADINA AND SODIUM CHLORIDE, TEPADINA
Application NDA208264
Aleve — NAPROXEN SODIUM
Application NDA021920
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)